In conclusion, this meta-analysis indicated that K-ras mutation is probably a valuable predictive biomarker for assessing the clinical response and survival outcomes of NSCLC patients treated with EGFR-TKIs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.